Pembrolizumab versus Ipilimumab in Advanced Melanoma
The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...
Publications
Explore 247 academic publications
Showing 12 of
247 publications
Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association
Background: The American Heart Association, in conjunction with the National Institutes of Health, annually reports the most up-to-date statistics related to heart disease, stro...
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Background: The American Heart Association, in conjunction with the National Institutes of Health, annually reports the most up-to-date statistics related to heart disease, stro...
Heart Disease and Stroke Statistics—2021 Update
Background: The American Heart Association, in conjunction with the National Institutes of Health, annually reports the most up-to-date statistics related to heart disease, stro...
Hepatocellular carcinoma
Hepatocellular carcinoma (HCC), one of the most frequent tumors in the world, is included by the World Health Organization as a relevant public health problem in areas of high i...
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Cancer treatment by immune checkpoint blockade (ICB) can bring long-lasting clinical benefits, but only a fraction of patients respond to treatment. To predict ICB response, we ...
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
In a phase 2 trial, lenvatinib, an inhibitor of VEGF receptors 1-3, FGF receptors 1-4, PDGF receptor α, RET, and KIT, showed activity in hepatocellular carcinoma. We aimed...
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Therapeutic antibodies that block the programmed death-1 (PD-1)–programmed death-ligand 1 (PD-L1) pathway can induce robust and durable responses in patients with various cancer...
A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance
Complex interventions are commonly used in the health and social care services, public health practice, and other areas of social and economic policy that have consequences for ...
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, ...
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
The international index and the age-adjusted international index should be used in the design of future therapeutic trials in patients with aggressive non-Hodgkin's lymphoma and...